(Q35677457)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1

Edith A Perez

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Ann E McCullough

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Monica M Reinholz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Kathleen S Tenner

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Nancy E Davidson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Julie Gralow

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Lyndsay N Harris

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Leila A Kutteh

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

David W Hillman

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Robert B Jenkins

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Beiyun Chen

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

English

0 references

publication date

2 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

Journal of the National Cancer Institute

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

159-162

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

17 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3260130

Adjuvant trastuzumab in HER2-positive breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3260130

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3260130

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3260130

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3260130

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3260130

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3260130

Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3260130

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3260130

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3260130

How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3260130

HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization

25 September 2018

1 reference

12 December 2020

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

1 reference

12 December 2020

Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study

1 reference

12 December 2020

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

12 December 2020

Identifiers

DOI

10.1093/JNCI/DJR490

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22138096%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference